肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

NEJM：阿那曲唑+氟维司群联合用药可延长乳腺癌患者生存

2012-08-03 爱维医学网 EGMN

阿那曲唑氟维司群延长乳腺癌患者生存
关注

8月2日《新英格兰医学杂志》发表的美国西南肿瘤协作组(SWOG)S0226 试验结果显示，阿那曲唑(瑞宁得)+氟维司群(芙仕得)联合用药方案可使初治的激素受体阳性转移性乳腺癌绝经后女性患者生命延长6个月。 加州大学欧文分校医学中心的Rita S. Mehta博士及其同事报告称，单纯阿那曲唑治疗组中位总生存期为41.3个月，而阿那曲唑+氟维司群联合治疗组为47.7个月。联合治疗组的生存优势还表

8月2日《新英格兰医学杂志》发表的美国西南肿瘤协作组(SWOG)S0226 试验结果显示，阿那曲唑(瑞宁得)+氟维司群(芙仕得)联合用药方案可使初治的激素受体阳性转移性乳腺癌绝经后女性患者生命延长6个月。

加州大学欧文分校医学中心的Rita S. Mehta博士及其同事报告称，单纯阿那曲唑治疗组中位总生存期为41.3个月，而阿那曲唑+氟维司群联合治疗组为47.7个月。联合治疗组的生存优势还表现在，尽管41%的对照组患者在疾病进展后改为氟维司群单药治疗，联合治疗组的死亡风险仍明显降低(HR，0.81)。中位无进展生存期(主要终点指标)也呈统计学显著性改善(13.5个月vs.15个月)。虽然3例死亡患者可能与联合用药治疗有关，但3~5级不良事件未见组间显著差异。

该项研究入组707例患者，其中694例纳入意向治疗分析。所有受试者均每天口服1 mg阿那曲唑，试验组还在第1天肌注500 mg负荷剂量的氟维司群，在第14和28天以及此后每28天给予250 mg的氟维司群。该剂量小于美国食品药品管理局(FDA)批准的500 mg剂量， 2011年2月2日修订后的方案允许两组患者在出现疾病进展后接受更大剂量的氟维司群治疗。

该研究由美国国立癌症研究所和阿斯利康公司资助。

链接：

Rita S. Mehta, M.D., William E. Barlow, Ph.D., Kathy S. Albain, M.D., Ted A. Vandenberg, M.D., Shaker R. Dakhil, M.D., Nagendra R. Tirumali, M.D., Danika L. Lew, M.A., Daniel F. Hayes, M.D., Julie R. Gralow, M.D., Robert B. Livingston, M.D., and Gabriel N. Hortobagyi, M.D.Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer.N Engl J Med 2012; 367:435-444

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932448, encodeId=1cf4193244821, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Aug 04 01:46:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412258, encodeId=3cee141225891, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514254, encodeId=61791514254a1, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570885, encodeId=6fb215e08855d, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=)]
    2012-08-04 tastas

    #患者生存#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1932448, encodeId=1cf4193244821, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Aug 04 01:46:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412258, encodeId=3cee141225891, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514254, encodeId=61791514254a1, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570885, encodeId=6fb215e08855d, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=)]
    2012-08-05 jiangfeng5068

    #阿那曲唑#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1932448, encodeId=1cf4193244821, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Aug 04 01:46:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412258, encodeId=3cee141225891, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514254, encodeId=61791514254a1, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570885, encodeId=6fb215e08855d, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=)]
    2012-08-05 ms4964546379600229

    #联合用药#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1932448, encodeId=1cf4193244821, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Aug 04 01:46:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412258, encodeId=3cee141225891, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514254, encodeId=61791514254a1, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570885, encodeId=6fb215e08855d, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Aug 05 01:46:00 CST 2012, time=2012-08-05, status=1, ipAttribution=)]
    2012-08-05 hanhaisha2013

    #乳腺癌患者#

    0